These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 27467849)

  • 1. Augmentation of the Susceptibility of Human Leukemia to Lymphokine-Activated Killer (LAK) Cells by Exposure of the Leukemic Target Cells to Cytotoxic Drugs in Vitro and in Vivo.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Lymphoma; 1991; 5(4):263-71. PubMed ID: 27467849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
    Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
    Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
    Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
    Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
    Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
    J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ewing's sarcoma: ex vivo sensitivity towards natural and lymphokine-activated killing.
    Atzpodien J; Gulati SC; Shimazaki C; Bührer C; Oz S; Kwon JH; Kolitz JE; Clarkson BD
    Oncology; 1988; 45(6):437-43. PubMed ID: 3263598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
    Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
    Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
    Kameda T; Negoro T; Hagiwara M; Koyama M; Matsuzaki N; Saji F; Tanizawa O
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
    Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
    Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The precursors and effectors of human lymphokine-activated killer (LAK) cells].
    Guo X
    Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):266-9, 317-8. PubMed ID: 8221242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.